AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 17259206
Drug: Citalopram 20
RxNorm normalized name: citalopram 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Citalopram 20 mg orally
Trial: 14679326
Drug: Buffered ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Buffered ibuprofen (800 mg ibuprofen + 200 mg magnesium hydroxide)
Trial: 14679326
Drug: Conventional ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Conventional ibuprofen (800 mg ibuprofen)
Trial: 11694865
Drug: Oral Disease
RxNorm normalized name: LYME DISEASE VACCINE
DrugBank: Lyme disease vaccine (recombinant OspA) (DB00045)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Disease Preventive Protocol including oral physiotherapy, non-alcoholic 0.05% fluoride mouthwashes, and topical application of myconazole oral gel
Trial: 11694865
Drug: Instructions on
RxNorm normalized name: Gel-One
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Instructions on oral physiotherapy
Trial: 3134468
Drug: Tertatolol 5
RxNorm normalized name: tertatolol 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tertatolol 5 mg with aspirin 1 g
Trial: 3134468
Drug: Aspirin 1
RxNorm normalized name: aspirin 125 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin 1 g
Trial: 8113843
Drug: High-dose cisplatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose cisplatin (120 mg/m2 IV on day 1)
Trial: 8113843
Drug: Moderate-dose cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Moderate-dose cisplatin (30 mg/m2 IV on days 2 and 3) and carboplatin (200 mg/m2 IV on day 1)
Trial: 8113843
Drug: Moderate-dose cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Moderate-dose cisplatin and carboplatin
Trial: 31155577
Drug: Magnesium oxide
RxNorm normalized name: Magnesium Oxide
DrugBank: Magnesium oxide (DB01377)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Magnesium oxide (MgO) co-administration
Trial: 26018671
Drug: Ketamine (0.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketamine (0.25 mg/kg bolus followed by 0.25 mg/kg/h infusion)
Trial: 26018671
Drug: Dexmedetomidine (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine (0.5 μg/kg bolus followed by 0.3 μg/kg/h infusion)
Trial: 16309554
Drug: Transpupillary therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transpupillary therapy (TTT) alone (Group A)
Trial: 16309554
Drug: Intravitreal triamcinolone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravitreal triamcinolone acetonide (iTA) 4 mg followed by TTT (Group B)
Trial: 11093285
Drug: Insulin (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insulin (1 mU/(kg min))
Trial: 8875584
Drug: 0.5 mg
RxNorm normalized name: biotin 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg terbutaline sulfate
Trial: 8875584
Drug: 1.0 mg
RxNorm normalized name: HYDROCORTISONE BUTYRATE 1.0 mg in 1 g TOPICAL CREAM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.0 mg terbutaline sulfate
Trial: 29732549
Drug: Eslicarbazepine acetate
RxNorm normalized name: Eslicarbazepine Acetate
DrugBank: Eslicarbazepine (DB14575)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Eslicarbazepine acetate (ESL) 800 mg QD
Trial: 29732549
Drug: Eslicarbazepine acetate
RxNorm normalized name: Eslicarbazepine Acetate
DrugBank: Eslicarbazepine (DB14575)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Eslicarbazepine acetate (ESL) 400 mg QD
Trial: 24297950
Drug: Temsirolimus 25
RxNorm normalized name: temsirolimus 25 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Temsirolimus 25 mg once weekly
Trial: 22459771
Drug: Inhaled budesonide
RxNorm normalized name: budesonide Inhalation Suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled budesonide (1,600 μg/d)
Trial: 12161519
Drug: Saline/Saline infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline/Saline infusion
Trial: 12161519
Drug: Saline/GHRH infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline/GHRH infusion
Trial: 12161519
Drug: rhGH infusion
RxNorm normalized name: rhGH
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rhGH infusion
Trial: 10334442
Drug: Adenosine infusion
RxNorm normalized name: Adenosine
DrugBank: Adenosine phosphate (DB00131)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Adenosine infusion (1, 10, 100, and 1,000 microg/min for 5 min each)
Trial: 10334442
Drug: Benazeprilat (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Benazeprilat (25 microg/min) during adenosine infusion
Trial: 61394
Drug: Prostaglandin E2
RxNorm normalized name: Prostaglandin E2
DrugBank: Dinoprostone (DB00917)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Prostaglandin E2 250 mug suspended in methyl ethyl cellulose ('Tylose') 6% solution
Trial: 27324934
Drug: Buccal infiltration
RxNorm normalized name: Autologous tumor infiltrating lymphocytes
DrugBank: Lifileucel (DB17107)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buccal infiltration of local anaesthesia (LA)
Trial: 27324934
Drug: Palatal injections
RxNorm normalized name: malate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Palatal injections of 0.1 ml 2% lidocaine with 1:100,000 adrenaline
Trial: 23292288
Drug: 10-g testosterone
RxNorm normalized name: lactulose
DrugBank: Lactulose (DB00581)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 10-g testosterone gel daily for 6 months
Trial: 20192950
Drug: 5‐HTTLPR genotype
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5‐HTTLPR genotype (L'L' vs S' allele) in males
Trial: 20192950
Drug: 5‐HTTLPR genotype
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5‐HTTLPR genotype (S'S' vs L' alleles) in females
Trial: 20192950
Drug: 5‐HTTLPR genotype
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5‐HTTLPR genotype (1 L' allele vs 2 L' alleles) in females
Trial: 12760869
Drug: Indinavir 1,200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indinavir 1,200 mg q12h
Trial: 12760869
Drug: Indinavir 1,000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indinavir 1,000 mg q8h
Trial: 12760869
Drug: Efavirenz 600
RxNorm normalized name: efavirenz 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Efavirenz 600 mg q24h
Trial: 12760869
Drug: Efavirenz 300
RxNorm normalized name: efavirenz 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Efavirenz 300 mg q12h
Trial: 12760869
Drug: Abacavir 300
RxNorm normalized name: abacavir 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Abacavir 300 mg q12h
Trial: 8334889
Drug: 0.5 mg
RxNorm normalized name: biotin 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg norethisterone (NET) per day
Trial: 8334889
Drug: 1.5 mg
RxNorm normalized name: boron 1.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.5 mg norethisterone (NET) per day
Trial: 8334889
Drug: 3.0 mg
RxNorm normalized name: TOBRAMYCIN 3.0 mg in 1 mL OPHTHALMIC SOLUTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3.0 mg norethisterone (NET) per day
Trial: 26876692
Drug: Hydroxychloroquine (HCQ)
DrugBank: Hydroxychloroquine (DB01611)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hydroxychloroquine (HCQ) treatment, mean blood concentration at V1: 660 ng/ml, at V2: 1020 ng/ml, mean difference 366 units, p < 0.001
Trial: 18562131
Drug: TPH1 (CC)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TPH1 (CC)
Trial: 18562131
Drug: HTR1A (Reference
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HTR1A (Reference CC)
Trial: 16202353
Drug: fentanyl 2
RxNorm normalized name: fentanyl 2.5 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: fentanyl 2 mg/kg
Trial: 16202353
Drug: esmolol 2
RxNorm normalized name: esmolol 20 mg/mL intravenous solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: esmolol 2 mg/kg
Trial: 10546921
Drug: Ketoconazole (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketoconazole (200 mg once daily for 5 days)
Trial: 1862217
Drug: Glycosaminoglycan polysulfate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glycosaminoglycan polysulfate (600 LRU daily for 12 weeks)
Trial: 30601950
Drug: Dolutegravir monotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dolutegravir monotherapy 50 mg once daily
Trial: 29691526
Drug: Black pepper-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Black pepper-based beverage (BPB) preload containing 20 mg gallic acid equivalent (GAE)
Trial: 26315860
Drug: Colchicine (administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Colchicine (administered for 3 months after an initial 3 months of observation)
Trial: 15498188
Drug: Spasfon (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spasfon (80 mg intravenously)
Trial: 15498188
Drug: Atropine (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atropine (0.5 mg injected into the cervix)
Trial: 11848259
Drug: Very-low-dose perindopril-indapamide
RxNorm normalized name: indapamide / perindopril
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Very-low-dose perindopril-indapamide combination
Trial: 11848259
Drug: Usual guidelines-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual guidelines-based treatment
Trial: 9865735
Drug: All-trans retinoic
RxNorm normalized name: all trans Retinoic acid
DrugBank: Tretinoin (DB00755)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All-trans retinoic acid (RA) therapy
Trial: 9865735
Drug: RA therapy
RxNorm normalized name: ALLANTOIN 0.5 g in 100 mL TOPICAL LOTION [ALRA THERAPY]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RA therapy after relapse
Trial: 7833225
Drug: Intra-articular injection
RxNorm normalized name: PHOSPHORUS P-32 5 mCi in 1 mL INTRA-ARTICULAR INJECTION, SUSPENSION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intra-articular injection of an aqueous solution containing paracetamol, salicylate, diclofenac, and [125I]-albumin (0.1 to 0.2 ml)
Trial: 3122349
Drug: Mannitol (preoperative
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mannitol (preoperative administration)
Trial: 24649919
Drug: Montelukast 10
RxNorm normalized name: montelukast 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Montelukast 10 mg daily for 2 weeks
Trial: 14598509
Drug: Hormone therapy
RxNorm normalized name: INVESTIGATIONAL HORMONE THERAPY/REPLACEMENT,OTHER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hormone therapy by progestagens and antiestrogens
Trial: 11304054
Drug: CHIK vaccine
RxNorm normalized name: CHIKUNGUNYA VACCINE
DrugBank: Chikungunya vaccine (live, attenuated) (DB18701)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CHIK vaccine
Trial: 1999706
Drug: MTX 200
RxNorm normalized name: MTX
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: MTX 200 mg/m2 followed by 5-FU 600 mg/m2 (arm A)
Trial: 1999706
Drug: MTX 200
RxNorm normalized name: MTX
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: MTX 200 mg/m2 followed by 5-FU 600 mg/m2 (arm B)
Trial: 6095656
Drug: H2-receptor antagonists
RxNorm normalized name: H2-receptor antagonists
FDA approved: no
EMA approved: no
PMDA approved: no
Description: H2-receptor antagonists (ranitidine and cimetidine)
Trial: 27142078
Drug: Twice daily
RxNorm normalized name: CAPSULE, TWICE DAILY
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Twice daily assisted exercise intervention (n = 13)
Trial: 27142078
Drug: Once daily
RxNorm normalized name: GEL, ONCE DAILY
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once daily assisted exercise intervention (n = 11)
Trial: 25315942
Drug: Esmolol (beta-blocker)
DrugBank: Esmolol (DB00187)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Esmolol (beta-blocker)
Trial: 21861845
Drug: ARB therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ARB therapy (losartan, 100 mg/day)
Trial: 12073199
Drug: Diltiazem (bolus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diltiazem (bolus 0.25 mg/kg followed by continuous infusion of 1.7 microg/kg/min) (DTZ, n = 12)
Trial: 9799972
Drug: Red ginseng
RxNorm normalized name: Red ginseng
DrugBank: Ginseng (DB01404)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Red ginseng (4.5 g/day)
Trial: 10759280
Drug: Glyceryl trinitrate
RxNorm normalized name: Glyceryl trinitrate
DrugBank: Nitroglycerin (DB00727)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Glyceryl trinitrate spray
Trial: 23024023
Drug: Directly Observed
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Directly Observed Inhaled Corticosteroid (DOICS) treatment with budesonide 1,600 μg for 7 days
Trial: 23024023
Drug: Directly Observed
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Directly Observed Inhaled Corticosteroid (DOICS) treatment with budesonide 1,600 μg for 5 days
Trial: 17627681
Drug: i.v. hydralazine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: i.v. hydralazine (5 mg doses)
Trial: 17627681
Drug: mini‐bolus diazoxide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mini‐bolus diazoxide (15 mg doses)
Trial: 12098159
Drug: Real low-level
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Real low-level laser therapy (LLLT) plus microamperes transcutaneous electric nerve stimulation (TENS)
Trial: 12098159
Drug: Sham low-level
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham low-level laser therapy (LLLT) plus microamperes transcutaneous electric nerve stimulation (TENS)
Trial: 7744087
Drug: Felodipine ER
RxNorm normalized name: Felodipine ER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Felodipine ER 10 mg o.m.
Trial: 7744087
Drug: Nifedipine SR
RxNorm normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nifedipine SR 20 mg b.d.
Trial: 6271049
Drug: Cefotaxime (1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefotaxime (1.0 g) intramuscularly
Trial: 6271049
Drug: Procaine penicillin
RxNorm normalized name: procaine penicillin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Procaine penicillin G (4.8 x 10(6) U) intramuscularly with 1 g of probenecid orally
Trial: 30642667
Drug: No oral
RxNorm normalized name: Beano Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No oral anticoagulation (non-OAC)
Trial: 28256356
Drug: 3 weeks
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 weeks of intensive speech and language therapy (≥10 hours per week)
Trial: 28256356
Drug: 3 weeks
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 weeks deferral of intensive speech and language therapy
Trial: 21177034
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (weekly information on general health)
Trial: 20355166
Drug: Testosterone (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Testosterone (250 mg Sustanon) administered weekly for five weeks
Trial: 17855669
Drug: High-dose melphalan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose melphalan plus autologous stem cells
Trial: 17855669
Drug: Melphalan plus
RxNorm normalized name: Melphalan
DrugBank: Melphalan (DB01042)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Melphalan plus high-dose dexamethasone
Trial: 17855669
Drug: High-dose melphalan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose melphalan plus autologous stem cells (low-risk disease)
Trial: 17855669
Drug: Melphalan plus
RxNorm normalized name: Melphalan
DrugBank: Melphalan (DB01042)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Melphalan plus high-dose dexamethasone (low-risk disease)
Trial: 17855669
Drug: High-dose melphalan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose melphalan plus autologous stem cells (high-risk disease)
Trial: 17855669
Drug: Melphalan plus
RxNorm normalized name: Melphalan
DrugBank: Melphalan (DB01042)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Melphalan plus high-dose dexamethasone (high-risk disease)
Trial: 9559773
Drug: Cefepime (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefepime (2 g administered every 12 h)
Trial: 9559773
Drug: Ceftriaxone (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ceftriaxone (1 g administered every 12 h)
Trial: 3665393
Drug: Ibuprofen 400
RxNorm normalized name: ibuprofen 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibuprofen 400 mg administered alone
Trial: 3665393
Drug: Ibuprofen 400
RxNorm normalized name: ibuprofen 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibuprofen 400 mg administered concurrently with antacid (62 mL of aluminum and magnesium hydroxide suspension)
Trial: 3665393
Drug: Ibuprofen 400
RxNorm normalized name: ibuprofen 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibuprofen 400 mg administered with antacid one hour after the ibuprofen dose
Trial: 3665393
Drug: Ibuprofen 400
RxNorm normalized name: ibuprofen 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibuprofen 400 mg administered concurrently with antacid plus three more antacid doses given every five hours
Trial: 23542612
Drug: Topical ketoprofen
RxNorm normalized name: ketoprofen Topical Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical ketoprofen 50 mg
Trial: 23542612
Drug: Topical ketoprofen
RxNorm normalized name: ketoprofen Topical Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical ketoprofen 100 mg
Trial: 23542612
Drug: Ketoprofen-free vehicle
RxNorm normalized name: Ketoprofen
DrugBank: Ketoprofen (DB01009)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ketoprofen-free vehicle 2.2 g (TDT 064)
Trial: 23542612
Drug: Ketoprofen-free vehicle
RxNorm normalized name: Ketoprofen
DrugBank: Ketoprofen (DB01009)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ketoprofen-free vehicle 4.4 g (TDT 064)
Trial: 23542612
Drug: Oral celecoxib
RxNorm normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral celecoxib 100 mg
Trial: 18218783
Drug: Isoproterenol infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isoproterenol infusion 1 (before fingolimod administration)
Trial: 18218783
Drug: Fingolimod administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fingolimod administration
Trial: 18218783
Drug: Isoproterenol infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isoproterenol infusion 2 (in the presence of fingolimod)
Trial: 18218783
Drug: Total isoproterenol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Total isoproterenol dose with fingolimod
Trial: 18218783
Drug: Isoproterenol infusions
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isoproterenol infusions 3 to 5
Trial: 11701431
Drug: GnRH agonist
RxNorm normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: GnRH agonist plus graded doses of testosterone
Trial: 11701431
Drug: Control (GnRH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (GnRH agonist only)
Trial: 9388519
Drug: RT and
RxNorm normalized name: Comfort and Ease KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RT and daily low dose of CDDP (5 mg/m2)
Trial: 8198916
Drug: Thiopentone 5.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thiopentone 5.1 mg kg‐1 with suxamethonium
Trial: 8198916
Drug: Propofol 2.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol 2.2 mg kg‐1 with suxamethonium
Trial: 22338818
Drug: Oral health
RxNorm normalized name: CETYLPYRIDINIUM CHLORIDE 0.07 g in 100 mL ORAL RINSE [Assured Oral Health Fresh Mint]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral health action plan including child's current caries-risk status, identification of issues of concern, and one goal to improve on for the next visit.
Trial: 12749510
Drug: Granisetron/dexamethasone combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Granisetron/dexamethasone combination (40 microg/kg granisetron + 8 mg dexamethasone)
Trial: 9170120
Drug: 300 mg
RxNorm normalized name: rutin 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg micronized progesterone administered in the evening
Trial: 8466015
Drug: 5 micrograms/mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 micrograms/mL norepinephrine
Trial: 8466015
Drug: 10 micrograms/mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 micrograms/mL norepinephrine
Trial: 8466015
Drug: 15 micrograms/mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 micrograms/mL norepinephrine
Trial: 8466015
Drug: Plain tetracaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plain tetracaine (0 micrograms/mL norepinephrine)
Trial: 31363043
Drug: Endovascular therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endovascular therapy favored by female physicians under ideal conditions
Trial: 31363043
Drug: Endovascular therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endovascular therapy favored by male physicians under ideal conditions
Trial: 31363043
Drug: Endovascular therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endovascular therapy favored by female physicians under current local resources
Trial: 31363043
Drug: Endovascular therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endovascular therapy favored by male physicians under current local resources
Trial: 31622158
Drug: β-alanine supplementation
RxNorm normalized name: Alanine
DrugBank: Alanine (DB00160)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: β-alanine supplementation (6.4 g/day) during HIIT
Trial: 18989245
Drug: h‐ANP (human
FDA approved: no
EMA approved: no
PMDA approved: no
Description: h‐ANP (human atrial natriuretic peptide) treatment, 0.02 microg/kg/min for 5 days or more
Trial: 18989245
Drug: h‐ANP treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: h‐ANP treatment
Trial: 18989245
Drug: non‐h‐ANP treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: non‐h‐ANP treatment (Group N)